DoD Kidney Cancer, Clinical Trial Award
ID: 355340Type: Posted
Overview

Buyer

Dept. of the Army -- USAMRAA (DOD-AMRAA)

Eligible Applicants

Unrestricted

Funding Category

Science and Technology and other Research and Development

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/355340
Timeline
    Description

    The Department of the Army, through the US Army Medical Research and Development Command (USAMRAA), is offering the Kidney Cancer Research Program (KCRP) Clinical Trial Award, aimed at advancing innovative clinical trials that significantly impact kidney cancer treatment and management. This grant supports a range of clinical trials, from pilot studies to large-scale projects, requiring preliminary data, access to suitable patient populations, and robust statistical analysis plans. With an estimated total program funding of $6.4 million, the program anticipates awarding approximately two grants, with applications due by October 15, 2024, following a Letter of Intent submission by September 24, 2024. Interested applicants can reach out to the CDMRP Help Desk at help@eBRAP.org for further assistance.

    Point(s) of Contact
    help@eBRAP.org
    Files
    Title
    Posted
    HT942524KCRPCTA_GG.pdf
    The DOD FY24 Kidney Cancer Clinical Trial Award is part of the Defense Health Program's Congressionally Directed Medical Research Programs aimed at advancing kidney cancer research. This grant seeks applications for rigorous, innovative clinical trials addressing kidney cancer, with a budget of $50 million for FY24. Key submission dates include the Letter of Intent due by September 24, 2024, and full applications by October 15, 2024. The program emphasizes understanding kidney cancer biology, developing new therapeutic strategies, improving patient care, and addressing health disparities, particularly for active duty military and veterans. Eligible applicants include organizations both within and outside the Department of Defense, while the funding initiative supports trials from pilot studies to larger-scale projects. The application process consists of a two-step submission, requiring a pre-application followed by a full application, with specific expectations for preliminary data, patient population access, and statistical analysis plans. This initiative is designed to catalyze impactful kidney cancer research that aligns with the strategic goals of the Kidney Cancer Research Program, ensuring that new discoveries translate into improved clinical outcomes for patients.
    Similar Opportunities
    Toxic Exposures Clinical Trial Award
    Active
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research and Development Command (USAMRAA), is offering a funding opportunity for the Fiscal Year 2024 Toxic Exposures Clinical Trial Award under the Toxic Exposures Research Program (TERP). This grant aims to support the rapid implementation of clinical trials that address health outcomes related to military-related toxic exposures, with a focus on prevention, treatment, and management of associated symptoms and diseases. The program emphasizes the importance of collaboration between the Department of Defense and the Department of Veterans Affairs, seeking proposals that align with specific program goals and topic areas, such as neurotoxin exposure and Gulf War Illness. The total estimated funding for this initiative is $10.4 million, with applications due by November 7, 2024. Interested applicants can reach out to the CDMRP Help Desk at help@eBRAP.org for further assistance.
    DoD VRP, Clinical Trial Award
    Active
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research Acquisition Activity (USAMRAA), is offering the FY24 Vision Clinical Trial Award to fund innovative clinical trials aimed at addressing eye injuries and visual dysfunctions related to military service. This grant opportunity supports early-phase clinical trials that evaluate new products, pharmacologic agents, and devices, with a focus on improving treatment outcomes for service-connected visual impairments. With an estimated total program funding of $2.56 million and an anticipated award amount of up to $1.6 million per application, interested applicants must submit their pre-applications by July 11, 2024, and full applications by November 8, 2024. For further inquiries, applicants can contact the CDMRP Help Desk at help@eBRAP.org or call 301-682-5507.
    Institutional Network Award for Promoting Kidney, Urologic, and Hematologic Research Training (U2C - Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the Institutional Network Award (U2C) to enhance training in kidney, urologic, and hematologic research. This funding opportunity aims to foster a collaborative environment by inviting institutions to submit a unified application that supports a cohort of trainees and early-career investigators, with a strong emphasis on partnerships among institutions within metropolitan areas. The initiative is crucial for reshaping research training and promoting scientific collaboration, ensuring that the next generation of researchers is equipped to address complex biomedical challenges. Applications will be accepted starting October 16, 2023, with a submission deadline of September 27, 2025. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov.
    Innovative Approaches for Reducing Disparities in Kidney Health
    Active
    Office of the Assistant Secretary for Health
    The Office of the Assistant Secretary for Health is forecasting a federal grant opportunity titled "Innovative Approaches for Reducing Disparities in Kidney Health" aimed at addressing chronic kidney disease (CKD) disparities through community-based strategies. This grant will support demonstration projects that adapt evidence-based approaches to reduce CKD and its related risk factors, particularly focusing on groups disproportionately affected by these health issues. With an estimated total program funding of $2 million, the agency anticipates awarding four grants, each ranging from $425,000 to $500,000, with applications due by February 11, 2025. Interested applicants can reach out to Alana Sutherland at OMHGrants@hhs.gov or by phone at 301-945-3668 for further information.
    Central Coordinating Site for the Polycystic Kidney Disease Research Core Centers (U24 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is soliciting applications for the Central Coordinating Site (CCS) for the Polycystic Kidney Disease (PKD) Research Core Centers through Funding Opportunity Number RFA-DK-25-015. The CCS will collaborate with four PKD Research Core Centers to enhance understanding of PKD and promote resource sharing, providing essential administrative support, managing data sharing, and administering pilot project funding. This initiative is crucial for fostering a diverse and collaborative research environment to address the challenges of PKD effectively. The funding opportunity anticipates approximately $1.1 million for one award in FY 2025, with annual budgets around $350,000. Interested applicants must submit their proposals via Grants.gov by November 14, 2024, and can direct inquiries to grantsinfo@nih.gov for further information.
    Catalytic Tool and Technology Development in Kidney, Urologic, and Hematologic Diseases (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Catalytic Tool and Technology Development in Kidney, Urologic, and Hematologic Diseases (R21 Clinical Trial Not Allowed)." This initiative aims to support the development of innovative tools and technologies that address significant challenges in kidney, urologic, and hematologic research, encouraging high-risk, exploratory projects that differ from traditional R01 grants. The funding, with a maximum budget of $275,000 over two years, is open to a diverse range of eligible applicants, including various educational institutions and community organizations, with applications due by January 7, 2025. For further details, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the official announcement at https://grants.nih.gov/grants/guide/pa-files/PAR-23-119.html.
    NCI Mentored Clinical Scientist Research Career Development Award to Promote Diversity (K08 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the NCI Mentored Clinical Scientist Research Career Development Award (K08), aimed at enhancing diversity within the cancer research workforce. This grant supports individuals from underrepresented backgrounds with clinical doctoral degrees, providing them with an intensive, mentored research experience over a period of 3-5 years, focused on biomedical, behavioral, and translational cancer research. The program is critical for developing the skills necessary to lead independent clinical trials and to prepare awardees for competitive research project grants, addressing significant health disparities in cancer research. Interested applicants must submit their proposals by January 7, 2025, and can find additional information at NIH Grants. For inquiries, contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov.
    NCI Mentored Research Scientist Development Award to Promote Diversity (K01 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the NCI Mentored Research Scientist Development Award to Promote Diversity (K01 Clinical Trial Required), aimed at enhancing diversity within the cancer research workforce. This grant provides salary and research support for individuals from underrepresented backgrounds who are committed to leading independent clinical trials, with a focus on fostering their career development through mentorship. The program is crucial for addressing health disparities in cancer outcomes and encourages applications from those facing systemic barriers in the field. Interested applicants can receive up to $100,000 annually for salaries and an additional $30,000 for research-related expenses, with applications due by November 12, 2024. For further inquiries, contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov or visit the additional information link at http://grants.nih.gov/grants/guide/pa-files/PAR-21-296.html.
    The NCI Worta McCaskill-Stevens Career Development Award for Community Oncology and Prevention Research (K12 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the Worta McCaskill-Stevens Career Development Award for Community Oncology and Prevention Research (K12), aimed at supporting newly trained clinicians committed to independent research careers in community oncology and cancer prevention. This grant opportunity encourages the development of community-based clinical trials and ancillary studies, with a strong emphasis on addressing health disparities and improving access to cancer clinical trials for underserved populations. Eligible applicants include a diverse range of organizations, particularly those serving underrepresented groups, with funding available for up to five years to support program planning and mentorship. Interested parties can find more information and application details at the NIH grants website, with the application deadline set for February 18, 2027.
    DOD Glioblastoma, Hypothesis Development Award
    Active
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research and Materiel Command (USAMRAA), is offering the Fiscal Year 2024 Glioblastoma Hypothesis Development Award, aimed at funding innovative research to improve glioblastoma patient outcomes. This grant supports exploratory projects that address significant issues in glioblastoma research, particularly in areas such as drug delivery and biomarker identification, without requiring preliminary data. The total estimated funding for this program is approximately $4.64 million, with an expected 13 awards to be made, each with a funding limit of $200,000 for single principal investigators and $300,000 for partnering teams, over a performance period of up to two years. Interested applicants must submit a Letter of Intent by November 6, 2024, followed by a full application by November 20, 2024; for further inquiries, contact the CDMRP Help Desk at help@eBRAP.org or 301-682-5507.